Australia's most trusted
source of pharma news
Posted 17 June 2026 AM
Four out of five health and life sciences leaders expect litigation in Australia to increase, and not everyone is prepared for it.
The Strategic Risk Signals: How life sciences leaders stay ahead of disputes in Australia report released by law firm MinterEllison highlights how mass-tort litigation that has succeeded in the United States has repeatedly migrated to Australia, in some cases leading to payouts in the hundreds of millions of dollars - and life science organisations in Australia need to take the pattern seriously.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.